



FibriArt - ECG Patch for Arrhythmia Diagnosis and Remote Patient Monitoring

- An intelligent medical device designed to capture a medical-grade ECG directly on a smartphone
- FibriArt records a single-lead ECG, supplying the patient and their physician with accurate and dependable insights into heart health, including diagnosis of arrhythmias such as Afib and AFL
- 4 FibriArt variants available for use in both acute and non-acute settings – 30 secs up to 28 days of patient monitoring
- FDA 510(k) submission expected March'25
- Currently seeking licensing / distribution partners in this rapidly-growing global market



Key Benefits of FibriArt

1. Simple & Comfortable for the Patient

- Simple to fit with minimal skin preparation
- Comfortable to wear - small, lightweight & discrete
- Durable and water-resistant - patients can wear during exercise, sleep & in the shower
- Long battery life - 7 days, then easily rechargeable
- Wearable up to 28 days (FibriArt X), replacing patch every 7 days
- User-friendly mobile app & cloud-based platform for remote monitoring, data analysis & patient engagement
- Easy to upload data via the mobile or desktop app - WiFi / Bluetooth connectivity

2. Detailed & Accurate for the Physician

- The FibriArt patch incorporates innovative printed conductive ink over textile substrates, eliminating any metallic or rigid skin-to-electrode point of contact
- This enhances the flexibility of the integrated device & significantly reduces motion artifacts compared to traditional metallic electrodes
- Full ECG wave-based analysis considers every aspect of the PQRST segment - multiple other wearable ECG devices use only RR interval data for prediction
- FDA 510(k) submission expected March'25

3. Clinically Efficient




- Cloud-based AI algorithms automate arrhythmia detection, ECG interpretation & event classification
- Easy navigation on Fibriart's cloud-based platform allows physician to quickly & remotely view & analyse ECG
- No need to scroll over long term ECG data to identify anomalies - the physician receives a fully automated, easy-to-read comprehensive report
- In primary care, FibriArt is expected to shift the point of arrhythmia diagnosis earlier in the patient care cycle

4. Cost Efficient & Commercial


- Expected that 4 FibriArt variants will be available for use in acute and non-acute settings
- Electrode patches manufactured in the EU
- Devices assembled in-house at Topia Life Sciences Ltd.'s dedicated facility in India
- Expecting highly competitive supply pricing at volume manufacturing
- ECG patch market is forecast to grow rapidly, driven by growing prevalence of Afib, aging and rising incidence of cardiovascular disorders

Mobile App for iOS or Android WiFi / Bluetooth connectivity

TOPIA
LIFE SCIENCES



PC Dashboard



Contact:

- FibriArt has been developed by Topia Life Sciences - www.topialifesciences.com
- Headquartered in the UK, with a team of 85 engineers and scientists in India, Topia is an innovative growth-stage TechBio company transforming life sciences with advanced AI-driven platforms, products and services.
- For further information, or for licensing / distribution enquiries, please contact: info@topialifesciences.com



Important Disclaimer

Currently FibriArt is under process for submission of 510(K) & CE mark.

Once FibriArt is approved for 510(k) & CE mark, it will be available to respective countries for sale.